Literature DB >> 7749326

Ras signaling and NF1.

F McCormick1.   

Abstract

The gene responsible for the hereditary disease neurofibromatosis type 1 (NF1) has been well characterized as a regulator of Ras protein activity. Many aspects of the disease seem to be caused by misregulation of Ras as a result of NF1 mutation. Other aspects, however, point at functions for the NF1 protein that have yet to be discovered.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7749326     DOI： 10.1016/s0959-437x(95)90053-5

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  19 in total

1.  Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation.

Authors:  Seung Tae Baek; Michelle D Tallquist
Journal:  Development       Date:  2012-04-25       Impact factor: 6.868

2.  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Authors:  Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; David Janhofer; Eva Dombi; Richard S Dunn; Mi-Ok Kim; Andrea R Masters; David R Jones; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2015-04-22       Impact factor: 3.167

3.  Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control.

Authors:  D Qian; D Zhou; R Ju; C L Cramer; Z Yang
Journal:  Plant Cell       Date:  1996-12       Impact factor: 11.277

4.  Runx1 contributes to neurofibromatosis type 1 neurofibroma formation.

Authors:  H Li; X Zhao; X Yan; W J Jessen; M-O Kim; E Dombi; P P Liu; G Huang; J Wu
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

5.  Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Authors:  Kiran S Choudhry; Monica Grover; Alyssa A Tran; E O'Brian Smith; Kenneth J Ellis; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2012-04-11       Impact factor: 4.797

6.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

7.  Neurofibromatosis with gastrointestinal stromal tumors: insights into the association.

Authors:  Shih-Ping Cheng; Ming-Jer Huang; Tsen-Long Yang; Chin-Yuan Tzen; Chien-Liang Liu; Tsang-Pai Liu; Shu-Ching Hsiao
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 8.  Lessons from the p53 mutant mouse.

Authors:  T Jacks
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

10.  Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.

Authors:  S J Miller; Z D Lan; A Hardiman; J Wu; J J Kordich; D M Patmore; R S Hegde; T P Cripe; J A Cancelas; M H Collins; N Ratner
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.